Analysts Offer Insights on Healthcare Companies: Spectranetics (NASDAQ: SPNC), Pacira Pharmaceuticals (NASDAQ: PCRX) and Omeros Corp. (NASDAQ: OMER)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectranetics (NASDAQ: SPNC), Pacira Pharmaceuticals (NASDAQ: PCRX) and Omeros Corp. (NASDAQ: OMER) with bullish sentiments.

Spectranetics (NASDAQ: SPNC)

In a report released today, Jason Mills from Canaccord Genuity reiterated a Buy rating on Spectranetics (NASDAQ: SPNC), with a price target of $30. The company’s shares opened today at $22.05.

According to TipRanks.com, Mills is a 1-star analyst with an average return of -0.6% and a 52.1% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

Currently, the analyst consensus on Spectranetics is Strong Buy and the average price target is $30.67, representing a 39.1% upside.

In a report issued on October 21, Needham also reiterated a Buy rating on the stock with a $32 price target.
Pacira Pharmaceuticals (NASDAQ: PCRX)

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $64. The company’s shares opened today at $32.75, close to its 52-week low of $30.60.

Rivkind Koffler said:

“We will update our recommendation and price target after the earnings call. Catalysts and other news: Mgmt indicated that during the quarter, it had manufacturing issues related to failed Exparel batches and took a $21.9M charge to COGS, which was adjusted out. In late 2016 we still expect mgmt to present data from its head-to-head trial in total knee arthroplasty, which it hopes may drive a switch away from generic cocktails to Exparel.”

According to TipRanks.com, Koffler is a top 100 analyst with an average return of 15.2% and a 43.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Adamas Pharmaceuticals.

Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $64, representing a 95.4% upside.

In a report issued on October 19, Wedbush also reiterated a Buy rating on the stock with a $93 price target.
Omeros Corp. (NASDAQ: OMER)

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Omeros Corp. (NASDAQ: OMER), with a price target of $19. The company’s shares opened today at $8.35, close to its 52-week low of $7.20.

Kolbert noted:

“Financial update. Omeros recently announced that a new $125M credit facility with the healthcare-focused investment firm CRG LP is now in place. Omeros will initially draw $80M, $76M of which will be used to pay off existing loans. An additional $45M can be drawn in two tranches through YE17.”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -16.6% and a 25.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Brainstorm Cell Therapeutics, and ImmunoCellular Therapeutics.

Currently, the analyst consensus on Omeros Corp. is Strong Buy and the average price target is $65.50, representing a 684.4% upside.

In a report issued on October 18, Wedbush also reiterated a Buy rating on the stock with a $56 price target.